Panitumumab

Search with Google Search with Bing

Information
Drug Name
Panitumumab
Description
Entry(CIViC)
52
CIViC
Disease Mutation EL ET ED CS VO TR Pubmed Links
colorectal cancer AREG EXPRESSION AREG EXPRESSION B Predictive Supports Sensitivity/Response N/A 4 26867820 Detail
colorectal cancer EREG EXPRESSION EREG EXPRESSION B Predictive Supports Sensitivity/Response N/A 4 26867820 Detail
colorectal cancer EGFR p.Gly465Arg (p.G465R)
( ENST00000455089.5, ENST00000275493.7, ENST00000342916.7, ENST00000344576.7, ENST00000450046.2 ) EGFR p.Gly465Arg (p.G465R)
( ENST00000275493.7, ENST00000342916.7, ENST00000344576.7, ENST00000450046.2, ENST00000455089.5 ) 		C Predictive Supports Resistance Somatic 4 26888827 Detail
colorectal cancer EGFR p.Ser492Arg (p.S492R)
( ENST00000275493.7, ENST00000342916.7, ENST00000344576.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Ser492Arg (p.S492R)
( ENST00000275493.7, ENST00000342916.7, ENST00000344576.7, ENST00000450046.2, ENST00000455089.5 ) 		C Predictive Supports Sensitivity/Response Somatic 2 22270724 Detail
colorectal cancer EGFR p.Ser492Arg (p.S492R)
( ENST00000275493.7, ENST00000342916.7, ENST00000344576.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Ser492Arg (p.S492R)
( ENST00000275493.7, ENST00000342916.7, ENST00000344576.7, ENST00000450046.2, ENST00000455089.5 ) 		D Predictive Supports Sensitivity/Response Somatic 4 26888827 Detail
colorectal cancer EGFR p.Arg451Cys (p.R451C)
( ENST00000275493.7, ENST00000342916.7, ENST00000344576.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Arg451Cys (p.R451C)
( ENST00000275493.7, ENST00000342916.7, ENST00000344576.7, ENST00000450046.2, ENST00000455089.5 ) 		D Predictive Supports Sensitivity/Response Somatic 2 26888827 Detail
colorectal cancer EGFR p.Lys467Thr (p.K467T)
( ENST00000275493.7, ENST00000342916.7, ENST00000344576.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Lys467Thr (p.K467T)
( ENST00000275493.7, ENST00000342916.7, ENST00000344576.7, ENST00000450046.2, ENST00000455089.5 ) 		D Predictive Supports Sensitivity/Response Somatic 3 26888827 Detail
colon mucinous adenocarcinoma KRAS p.Gln22Ter (p.Q22*)
( ENST00000256078.10, ENST00000686969.1, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gln22Ter (p.Q22*)
( ENST00000685328.1, ENST00000557334.6, ENST00000256078.10, ENST00000688940.1, ENST00000686969.1, ENST00000311936.8, ENST00000692768.1, ENST00000556131.2, ENST00000693229.1 ) 		C Predictive Supports Resistance Somatic 2 19661358 Detail
colorectal cancer BRAF MUTATION BRAF MUTATION B Predictive Does Not Support Sensitivity/Response Somatic 3 25673558 Detail
colorectal cancer BRAF p.Val640Glu (p.V640E)
( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E)
( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) 		B Predictive Does Not Support Sensitivity/Response Somatic 3 25589621 Detail
colorectal cancer BRAF p.Asp634Gly (p.D634G)
( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Asp634Gly (p.D634G)
( ENST00000646891.2, ENST00000496384.7, ENST00000644969.2, ENST00000288602.11 ) 		C Predictive Does Not Support Resistance Somatic 1 27404270 Detail
colorectal cancer BRAF p.Val640Glu (p.V640E)
( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E)
( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) 		C Predictive Supports Sensitivity/Response Somatic 2 27325282 Detail
colorectal cancer ERBB2 AMPLIFICATION
( ENST00000269571.10 ) ERBB2 AMPLIFICATION
( ENST00000269571.10 ) 		B Predictive Supports Resistance N/A 2 23348520 Detail
colorectal cancer EGFR EXPRESSION EGFR EXPRESSION B Predictive Supports Sensitivity/Response N/A 2 17470858 Detail
colorectal cancer KRAS p.Gly12Ala (p.G12A)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly12Ala (p.G12A)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000692768.1, ENST00000693229.1, ENST00000686969.1, ENST00000688940.1 ) 		C Predictive Supports Resistance Somatic 18316791 Detail
colorectal cancer PIK3CA p.Glu545Lys (p.E545K)
( ENST00000263967.4, ENST00000643187.1 ) PIK3CA p.Glu545Lys (p.E545K)
( ENST00000263967.4, ENST00000643187.1 ) 		C Predictive Does Not Support Resistance Somatic 2 19223544 Detail
colorectal cancer BRAF p.Val640Glu (p.V640E)
( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E)
( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) 		B Predictive Supports Resistance Somatic 3 19001320 Detail
colorectal cancer KRAS p.Gly13Asp (p.G13D)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000685328.1, ENST00000557334.6, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly13Asp (p.G13D)
( ENST00000556131.2, ENST00000557334.6, ENST00000256078.10, ENST00000311936.8, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) 		C Predictive Supports Resistance Somatic 18316791 Detail
colorectal cancer KRAS p.Gly12Val (p.G12V)
( ENST00000688940.1, ENST00000692768.1, ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000693229.1 ) KRAS p.Gly12Val (p.G12V)
( ENST00000693229.1, ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1 ) 		C Predictive Supports Resistance Somatic 18316791 Detail
colorectal cancer KRAS p.Gly12Asp (p.G12D)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly12Asp (p.G12D)
( ENST00000692768.1, ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000693229.1 ) 		C Predictive Supports Resistance Somatic 18316791 Detail
colorectal cancer KRAS p.Gly12Cys (p.G12C)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly12Cys (p.G12C)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) 		C Predictive Supports Resistance Somatic 18316791 Detail
colorectal cancer KRAS p.Gly12Arg (p.G12R)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000692768.1, ENST00000686969.1, ENST00000688940.1, ENST00000693229.1 ) KRAS p.Gly12Arg (p.G12R)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) 		C Predictive Supports Resistance Somatic 18316791 Detail
colorectal cancer KRAS p.Gly12Ser (p.G12S)
( ENST00000685328.1, ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly12Ser (p.G12S)
( ENST00000256078.10, ENST00000311936.8, ENST00000685328.1, ENST00000686969.1, ENST00000556131.2, ENST00000557334.6, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) 		C Predictive Supports Resistance Somatic 18316791 Detail
colorectal cancer PIK3CA p.Glu542Lys (p.E542K)
( ENST00000643187.1, ENST00000263967.4 ) PIK3CA p.Glu542Lys (p.E542K)
( ENST00000263967.4, ENST00000643187.1 ) 		B Predictive Supports Resistance Somatic 3 19223544 Detail
colorectal cancer PIK3CA p.His1047Arg (p.H1047R)
( ENST00000263967.4, ENST00000643187.1 ) PIK3CA p.His1047Arg (p.H1047R)
( ENST00000263967.4, ENST00000643187.1 ) 		B Predictive Does Not Support Resistance Somatic 2 19223544 Detail
colorectal cancer BRAF V600E AMPLIFICATION
( ENST00000288602.11 ) BRAF V600E AMPLIFICATION
( ENST00000288602.11 ) 		C Predictive Supports Resistance Somatic 3 25673644 Detail
colorectal cancer PIK3CA p.Glu545Lys (p.E545K)
( ENST00000263967.4, ENST00000643187.1 ) PIK3CA p.Glu545Lys (p.E545K)
( ENST00000263967.4, ENST00000643187.1 ) 		C Predictive Supports Resistance Somatic 3 19223544 Detail
colorectal cancer PIK3CA p.His1047Arg (p.H1047R)
( ENST00000263967.4, ENST00000643187.1 ) PIK3CA p.His1047Arg (p.H1047R)
( ENST00000263967.4, ENST00000643187.1 ) 		C Predictive Supports Resistance Somatic 2 19223544 Detail
colorectal cancer NRAS MUTATION NRAS MUTATION A Predictive Supports Resistance Somatic 4 28275037 Detail
colorectal cancer KRAS MUTATION KRAS MUTATION A Predictive Supports Resistance Somatic 5 28275037 Detail
cholangiocarcinoma BRAF p.Val640Glu (p.V640E)
( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E)
( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) 		C Predictive Supports Sensitivity/Response Somatic 3 26687137 Detail
colorectal cancer BRAF p.Val640Glu (p.V640E)
( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E)
( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) 		B Predictive Supports Sensitivity/Response Somatic 4 29431699 Detail
colorectal adenocarcinoma BRAF p.Val640Glu (p.V640E)
( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E)
( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) 		B Predictive Does Not Support Sensitivity/Response Somatic 3 29431699 Detail
colorectal cancer KRAS p.Gly13Val (p.G13V)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly13Val (p.G13V)
( ENST00000686969.1, ENST00000688940.1, ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000692768.1, ENST00000693229.1 ) 		C Predictive Supports Resistance Somatic 2 19223544 Detail
colorectal cancer KRAS p.Gly12Ser (p.G12S)
( ENST00000685328.1, ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly12Ser (p.G12S)
( ENST00000256078.10, ENST00000311936.8, ENST00000685328.1, ENST00000686969.1, ENST00000556131.2, ENST00000557334.6, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) 		C Predictive Supports Resistance Somatic 2 19223544 Detail
colorectal cancer PTEN DELETION
( ENST00000371953.8 ) PTEN DELETION
( ENST00000371953.8 ) 		B Predictive Supports Resistance Somatic 3 19223544 Detail
colorectal cancer KRAS p.Gly12Asp (p.G12D)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly12Asp (p.G12D)
( ENST00000692768.1, ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000693229.1 ) 		C Predictive Supports Resistance Somatic 2 19223544 Detail
colorectal cancer KRAS p.Gly12Ala (p.G12A)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly12Ala (p.G12A)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000692768.1, ENST00000693229.1, ENST00000686969.1, ENST00000688940.1 ) 		C Predictive Supports Resistance Somatic 2 19223544 Detail
colorectal cancer KRAS p.Gly13Asp (p.G13D)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000685328.1, ENST00000557334.6, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly13Asp (p.G13D)
( ENST00000556131.2, ENST00000557334.6, ENST00000256078.10, ENST00000311936.8, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) 		C Predictive Does Not Support Resistance Somatic 2 19223544 Detail
colorectal cancer KRAS p.Gly13Asp (p.G13D)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000685328.1, ENST00000557334.6, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly13Asp (p.G13D)
( ENST00000556131.2, ENST00000557334.6, ENST00000256078.10, ENST00000311936.8, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) 		C Predictive Supports Resistance Somatic 2 19223544 Detail
colorectal cancer KRAS p.Gly12Val (p.G12V)
( ENST00000688940.1, ENST00000692768.1, ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000693229.1 ) KRAS p.Gly12Val (p.G12V)
( ENST00000693229.1, ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1 ) 		C Predictive Supports Resistance Somatic 2 19223544 Detail
colorectal cancer PIK3CA MUTATION PIK3CA MUTATION B Predictive Supports Resistance Somatic 3 19223544 Detail
colorectal cancer KRAS G12/G13 KRAS G12/G13 B Predictive Supports Resistance Somatic 3 19223544 Detail
head and neck squamous cell carcinoma CDKN2A p16 EXPRESSION CDKN2A p16 EXPRESSION B Predictive Supports Resistance Somatic 3 23746666 Detail
colorectal cancer FBXW7 MUTATION FBXW7 MUTATION B Predictive Supports Resistance Somatic 2 26508446 Detail
colorectal cancer SMAD4 MUTATION SMAD4 MUTATION B Predictive Supports Resistance Somatic 2 26508446 Detail
head and neck squamous cell carcinoma CDKN2A p16 EXPRESSION CDKN2A p16 EXPRESSION B Predictive Supports Sensitivity/Response Somatic 3 23746666 Detail
colorectal cancer BRAF p.Gly506Val (p.G506V)
( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Gly506Val (p.G506V)
( ENST00000288602.11, ENST00000646891.2, ENST00000496384.7, ENST00000644969.2 ) 		D Predictive Supports Sensitivity/Response Somatic 3 28783719 Detail
colorectal cancer BRAF p.Val640Glu (p.V640E)
( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E)
( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) 		B Predictive Does Not Support Resistance Somatic 4 25989278 Detail
colorectal cancer EGFR AMPLIFICATION
( ENST00000275493.7 ) EGFR AMPLIFICATION
( ENST00000275493.7 ) 		B Predictive Supports Sensitivity/Response Somatic 3 24653627 Detail
colorectal cancer BRAF V600 BRAF V600 B Predictive Supports Resistance Somatic 3 23325582 Detail
colorectal cancer BRAF p.Val640Glu (p.V640E)
( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E)
( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) 		D Predictive Supports Sensitivity/Response Somatic 3 19001320 Detail
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
Prospectively planned retrospective biomarker stud... AREG AREG EXPRESSION AREG EXPRESSION Sensitivity true CIViC Evidence detail
Prospectively planned retrospective biomarker stud... EREG EREG EXPRESSION EREG EXPRESSION Sensitivity true CIViC Evidence detail
An EGFR G465R mutation (22% of mutant alleles) was... EGFR EGFR p.Gly465Arg (p.G465R)
( ENST00000455089.5, ENST00000275493.7, ENST00000342916.7, ENST00000344576.7, ENST00000450046.2 ) EGFR p.Gly465Arg (p.G465R)
( ENST00000275493.7, ENST00000342916.7, ENST00000344576.7, ENST00000450046.2, ENST00000455089.5 ) 		Resitance or Non-Reponse true CIViC Evidence detail
Tumor sequencing in pre- and post-therapy specimen... EGFR EGFR p.Ser492Arg (p.S492R)
( ENST00000275493.7, ENST00000342916.7, ENST00000344576.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Ser492Arg (p.S492R)
( ENST00000275493.7, ENST00000342916.7, ENST00000344576.7, ENST00000450046.2, ENST00000455089.5 ) 		Sensitivity true CIViC Evidence detail
In this preclinical study of cetuximab, panitumuma... EGFR EGFR p.Ser492Arg (p.S492R)
( ENST00000275493.7, ENST00000342916.7, ENST00000344576.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Ser492Arg (p.S492R)
( ENST00000275493.7, ENST00000342916.7, ENST00000344576.7, ENST00000450046.2, ENST00000455089.5 ) 		Sensitivity true CIViC Evidence detail
In this preclinical study on the effects of cetuxi... EGFR EGFR p.Arg451Cys (p.R451C)
( ENST00000275493.7, ENST00000342916.7, ENST00000344576.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Arg451Cys (p.R451C)
( ENST00000275493.7, ENST00000342916.7, ENST00000344576.7, ENST00000450046.2, ENST00000455089.5 ) 		Sensitivity true CIViC Evidence detail
In this preclinical study on the effects of cetuxi... EGFR EGFR p.Lys467Thr (p.K467T)
( ENST00000275493.7, ENST00000342916.7, ENST00000344576.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Lys467Thr (p.K467T)
( ENST00000275493.7, ENST00000342916.7, ENST00000344576.7, ENST00000450046.2, ENST00000455089.5 ) 		Sensitivity true CIViC Evidence detail
A 43-year-old female was diagnosed with an adenoca... KRAS KRAS p.Gln22Ter (p.Q22*)
( ENST00000256078.10, ENST00000686969.1, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gln22Ter (p.Q22*)
( ENST00000685328.1, ENST00000557334.6, ENST00000256078.10, ENST00000688940.1, ENST00000686969.1, ENST00000311936.8, ENST00000692768.1, ENST00000556131.2, ENST00000693229.1 ) 		Resitance or Non-Reponse true CIViC Evidence detail
A quantitative synthesis was performed on nine stu... BRAF BRAF MUTATION BRAF MUTATION Sensitivity false CIViC Evidence detail
Treatment response to mutant BRAF inhibitor vemura... BRAF BRAF p.Val640Glu (p.V640E)
( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E)
( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) 		Sensitivity false CIViC Evidence detail
Two patients with stage IV BRAF (D594G) mutations ... BRAF BRAF p.Asp634Gly (p.D634G)
( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Asp634Gly (p.D634G)
( ENST00000646891.2, ENST00000496384.7, ENST00000644969.2, ENST00000288602.11 ) 		Resitance or Non-Reponse false CIViC Evidence detail
Case report of a patient with BRAF V600E mutant me... BRAF BRAF p.Val640Glu (p.V640E)
( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E)
( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) 		Sensitivity true CIViC Evidence detail
HER2 amplification (FISH) was assessed in 170 KRAS... ERBB2 ERBB2 AMPLIFICATION
( ENST00000269571.10 ) ERBB2 AMPLIFICATION
( ENST00000269571.10 ) 		Resitance or Non-Reponse true CIViC Evidence detail
463 patients with 1% or more EGFR tumor cell membr... EGFR EGFR EXPRESSION EGFR EXPRESSION Sensitivity true CIViC Evidence detail
In a retrospective study of 427 metastatic colorec... KRAS KRAS p.Gly12Ala (p.G12A)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly12Ala (p.G12A)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000692768.1, ENST00000693229.1, ENST00000686969.1, ENST00000688940.1 ) 		Resitance or Non-Reponse true CIViC Evidence detail
In this study, a large cohort of metastatic colore... PIK3CA PIK3CA p.Glu545Lys (p.E545K)
( ENST00000263967.4, ENST00000643187.1 ) PIK3CA p.Glu545Lys (p.E545K)
( ENST00000263967.4, ENST00000643187.1 ) 		Resitance or Non-Reponse false CIViC Evidence detail
In metastatic colorectal cancer patients with wild... BRAF BRAF p.Val640Glu (p.V640E)
( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E)
( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) 		Resitance or Non-Reponse true CIViC Evidence detail
In a retrospective study of 427 metastatic colorec... KRAS KRAS p.Gly13Asp (p.G13D)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000685328.1, ENST00000557334.6, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly13Asp (p.G13D)
( ENST00000556131.2, ENST00000557334.6, ENST00000256078.10, ENST00000311936.8, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) 		Resitance or Non-Reponse true CIViC Evidence detail
In a retrospective study of 427 metastatic colorec... KRAS KRAS p.Gly12Val (p.G12V)
( ENST00000688940.1, ENST00000692768.1, ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000693229.1 ) KRAS p.Gly12Val (p.G12V)
( ENST00000693229.1, ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1 ) 		Resitance or Non-Reponse true CIViC Evidence detail
In a retrospective study of 427 metastatic colorec... KRAS KRAS p.Gly12Asp (p.G12D)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly12Asp (p.G12D)
( ENST00000692768.1, ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000693229.1 ) 		Resitance or Non-Reponse true CIViC Evidence detail
In a retrospective study of 427 metastatic colorec... KRAS KRAS p.Gly12Cys (p.G12C)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly12Cys (p.G12C)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) 		Resitance or Non-Reponse true CIViC Evidence detail
In a retrospective study of 427 metastatic colorec... KRAS KRAS p.Gly12Arg (p.G12R)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000692768.1, ENST00000686969.1, ENST00000688940.1, ENST00000693229.1 ) KRAS p.Gly12Arg (p.G12R)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) 		Resitance or Non-Reponse true CIViC Evidence detail
In a retrospective study of 427 metastatic colorec... KRAS KRAS p.Gly12Ser (p.G12S)
( ENST00000685328.1, ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly12Ser (p.G12S)
( ENST00000256078.10, ENST00000311936.8, ENST00000685328.1, ENST00000686969.1, ENST00000556131.2, ENST00000557334.6, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) 		Resitance or Non-Reponse true CIViC Evidence detail
The presence of a PIK3CA mutation in exon 9 (such ... PIK3CA PIK3CA p.Glu542Lys (p.E542K)
( ENST00000643187.1, ENST00000263967.4 ) PIK3CA p.Glu542Lys (p.E542K)
( ENST00000263967.4, ENST00000643187.1 ) 		Resitance or Non-Reponse true CIViC Evidence detail
In this study, a large cohort of metastatic colore... PIK3CA PIK3CA p.His1047Arg (p.H1047R)
( ENST00000263967.4, ENST00000643187.1 ) PIK3CA p.His1047Arg (p.H1047R)
( ENST00000263967.4, ENST00000643187.1 ) 		Resitance or Non-Reponse false CIViC Evidence detail
Paired pre-treatment and post-progression tumor bi... BRAF BRAF V600E AMPLIFICATION
( ENST00000288602.11 ) BRAF V600E AMPLIFICATION
( ENST00000288602.11 ) 		Resitance or Non-Reponse true CIViC Evidence detail
In this study, a large cohort of metastatic colore... PIK3CA PIK3CA p.Glu545Lys (p.E545K)
( ENST00000263967.4, ENST00000643187.1 ) PIK3CA p.Glu545Lys (p.E545K)
( ENST00000263967.4, ENST00000643187.1 ) 		Resitance or Non-Reponse true CIViC Evidence detail
In this study, a large cohort of metastatic colore... PIK3CA PIK3CA p.His1047Arg (p.H1047R)
( ENST00000263967.4, ENST00000643187.1 ) PIK3CA p.His1047Arg (p.H1047R)
( ENST00000263967.4, ENST00000643187.1 ) 		Resitance or Non-Reponse true CIViC Evidence detail
NCCN guidelines indicate colorectal cancer patient... NRAS NRAS MUTATION NRAS MUTATION Resitance or Non-Reponse true CIViC Evidence detail
NCCN guidelines indicate colorectal cancer patient... KRAS KRAS MUTATION KRAS MUTATION Resitance or Non-Reponse true CIViC Evidence detail
Patients with metastatic cholangiocarcinoma havori... BRAF BRAF p.Val640Glu (p.V640E)
( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E)
( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) 		Sensitivity true CIViC Evidence detail
In this trial, 142 patients with metastatic, BRAF ... BRAF BRAF p.Val640Glu (p.V640E)
( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E)
( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) 		Sensitivity true CIViC Evidence detail
In this trial, 142 patients with metastatic, BRAF ... BRAF BRAF p.Val640Glu (p.V640E)
( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E)
( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) 		Sensitivity false CIViC Evidence detail
In this study, a large cohort of metastatic colore... KRAS KRAS p.Gly13Val (p.G13V)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly13Val (p.G13V)
( ENST00000686969.1, ENST00000688940.1, ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000692768.1, ENST00000693229.1 ) 		Resitance or Non-Reponse true CIViC Evidence detail
In this study, a large cohort of metastatic colore... KRAS KRAS p.Gly12Ser (p.G12S)
( ENST00000685328.1, ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly12Ser (p.G12S)
( ENST00000256078.10, ENST00000311936.8, ENST00000685328.1, ENST00000686969.1, ENST00000556131.2, ENST00000557334.6, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) 		Resitance or Non-Reponse true CIViC Evidence detail
In this study, 81 metastatic colorectal cancer pat... PTEN PTEN DELETION
( ENST00000371953.8 ) PTEN DELETION
( ENST00000371953.8 ) 		Resitance or Non-Reponse true CIViC Evidence detail
In this study, a large cohort of metastatic colore... KRAS KRAS p.Gly12Asp (p.G12D)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly12Asp (p.G12D)
( ENST00000692768.1, ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000693229.1 ) 		Resitance or Non-Reponse true CIViC Evidence detail
In this study, a large cohort of metastatic colore... KRAS KRAS p.Gly12Ala (p.G12A)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly12Ala (p.G12A)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000692768.1, ENST00000693229.1, ENST00000686969.1, ENST00000688940.1 ) 		Resitance or Non-Reponse true CIViC Evidence detail
In this study, a large cohort of metastatic colore... KRAS KRAS p.Gly13Asp (p.G13D)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000685328.1, ENST00000557334.6, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly13Asp (p.G13D)
( ENST00000556131.2, ENST00000557334.6, ENST00000256078.10, ENST00000311936.8, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) 		Resitance or Non-Reponse false CIViC Evidence detail
In this study, a large cohort of metastatic colore... KRAS KRAS p.Gly13Asp (p.G13D)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000685328.1, ENST00000557334.6, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly13Asp (p.G13D)
( ENST00000556131.2, ENST00000557334.6, ENST00000256078.10, ENST00000311936.8, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) 		Resitance or Non-Reponse true CIViC Evidence detail
In this study, a large cohort of metastatic colore... KRAS KRAS p.Gly12Val (p.G12V)
( ENST00000688940.1, ENST00000692768.1, ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000693229.1 ) KRAS p.Gly12Val (p.G12V)
( ENST00000693229.1, ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1 ) 		Resitance or Non-Reponse true CIViC Evidence detail
Mutational analysis of 110 metastatic colorectal c... PIK3CA PIK3CA MUTATION PIK3CA MUTATION Resitance or Non-Reponse true CIViC Evidence detail
Mutational analysis of 109 metastatic colorectal c... KRAS KRAS G12/G13 KRAS G12/G13 Resitance or Non-Reponse true CIViC Evidence detail
In this retrospective analysis of p16 status as su... CDKN2A CDKN2A p16 EXPRESSION CDKN2A p16 EXPRESSION Resitance or Non-Reponse true CIViC Evidence detail
65 patients were retrospectively analyzed for muta... FBXW7 FBXW7 MUTATION FBXW7 MUTATION Resitance or Non-Reponse true CIViC Evidence detail
In a retrospective analysis of 65 patients with me... SMAD4 SMAD4 MUTATION SMAD4 MUTATION Resitance or Non-Reponse true CIViC Evidence detail
p16-negative patients (HPV negative) have a longer... CDKN2A CDKN2A p16 EXPRESSION CDKN2A p16 EXPRESSION Sensitivity true CIViC Evidence detail
In the study with a tumor from a patient with meta... BRAF BRAF p.Gly506Val (p.G506V)
( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Gly506Val (p.G506V)
( ENST00000288602.11, ENST00000646891.2, ENST00000496384.7, ENST00000644969.2 ) 		Sensitivity true CIViC Evidence detail
This meta-analysis of 7 randomized control trials ... BRAF BRAF p.Val640Glu (p.V640E)
( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E)
( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) 		Resitance or Non-Reponse false CIViC Evidence detail
In this meta-analysis (14 studies, 1021 patients),... EGFR EGFR AMPLIFICATION
( ENST00000275493.7 ) EGFR AMPLIFICATION
( ENST00000275493.7 ) 		Sensitivity true CIViC Evidence detail
In metastatic colorectal cancer patients with wild... BRAF BRAF V600 BRAF V600 Resitance or Non-Reponse true CIViC Evidence detail
Cetuximab or panitumumab may be ineffective in pat... BRAF BRAF p.Val640Glu (p.V640E)
( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E)
( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) 		Sensitivity true CIViC Evidence detail
NCT ID Status Phase Summary Start date Completion date
NCT03442569 Active, not recruiting Phase 2 PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC March 9, 2018 December 22, 2024
NCT05198934 Active, not recruiting Phase 3 Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation April 19, 2022 March 12, 2025
NCT03263429 Active, not recruiting Phase 1/Phase 2 Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer August 23, 2017 December 1, 2024
NCT04117945 Active, not recruiting Phase 2 Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer March 3, 2020 March 31, 2025
NCT03992456 Active, not recruiting Phase 2 Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer April 24, 2020 October 7, 2024
NCT03186326 Active, not recruiting Phase 2 Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer April 24, 2018 May 31, 2023
NCT04163952 Active, not recruiting Phase 1 Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin January 31, 2020 February 21, 2025
NCT03087071 Active, not recruiting Phase 2 Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer December 29, 2017 January 31, 2025
NCT03983993 Active, not recruiting Phase 2 Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer October 15, 2019 October 31, 2024
NCT02876107 Active, not recruiting Phase 2 Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer October 6, 2016 October 31, 2025
NCT05084859 Active, not recruiting Phase 1 A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors November 3, 2021 July 2026
NCT02593175 Active, not recruiting Phase 2 Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC August 26, 2016 August 31, 2025
NCT01801904 Active, not recruiting Phase 2 A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer December 2012 December 2024
NCT01312857 Active, not recruiting Phase 2 Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer March 2011 March 2025
NCT03635021 Active, not recruiting Phase 3 Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer October 15, 2018 June 28, 2025
NCT00418938 Completed Phase 2 SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial November 1, 2006 April 1, 2013
NCT00446446 Completed Phase 2 PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer) October 30, 2007 November 29, 2017
NCT00454779 Completed Phase 2 PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response January 1, 2007 January 1, 2014
NCT00500760 Completed Phase 2 Study of Addition of Panitumumab to Chemoradiation Therapy in Patients With Locally Advanced Head and Neck Cancer October 1, 2007 April 26, 2011
NCT00508404 Completed Phase 2 Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer May 9, 2007 June 12, 2012
NCT00513383 Completed Phase 1 Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck April 2006 October 2012
NCT00547157 Completed Phase 2 Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck November 2007 March 2012
NCT00550836 Completed Phase 2 Erlotinib and Gemcitabine With or Without Panitumumab in Treating Patients With Metastatic Pancreatic Cancer March 2009 May 2013
NCT00563316 Completed Phase 1 Effect of Panitumumab on the Pharmacokinetics of Irinotecan March 2008 June 2010
NCT00578071 Completed Phase 1/Phase 2 Phase I/II Study of Panitumumab, Capecitabine and Oxaliplatin w EBRT for Esophageal Cancer December 2007 June 2012
NCT00601627 Completed Phase 2 Panitumumab, Chemotherapy, and External-Beam Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot be Removed by Surgery June 2009 May 2013
NCT00610948 Completed Phase 1 Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Tumors That Did Not Respond to Treatment March 2008 January 2016
NCT00630786 Completed Phase 1/Phase 2 Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study January 2008 November 2010
NCT00655499 Completed Phase 2 Panitumumab and Irinotecan as Third-Line Therapy in Treating Patients With Metastatic Colorectal Cancer June 2008 June 2012
NCT00658658 Completed Phase 1 Panitumumab in Children With Solid Tumors March 2008 March 2015
NCT00756444 Completed Phase 2 A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck October 21, 2008 March 30, 2012
NCT00757172 Completed Phase 2 Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction January 2009 December 2014
NCT00788957 Completed Phase 1/Phase 2 Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC) October 2008 October 2013
NCT00792363 Completed Phase 2 Irinotecan and Panitumumab as 3rd Line Treatment for mCRC Without KRAS Mutations November 2008 August 2011
NCT00798655 Completed Phase 2 Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer November 2007 November 9, 2016
NCT00004879 Completed Phase 1 Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer April 2000
NCT00819780 Completed Phase 2 PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors April 24, 2009 July 7, 2016
NCT00820248 Completed Phase 3 Radiation + Cisplatin or Panitumumab in Locally Advanced Stage III or Stage IV Head and Neck Cancer December 30, 2008 February 17, 2017
NCT00836277 Completed Phase 2 Phase II Study of Irinotecan and Panitumumab May 2009 August 2015
NCT00842257 Completed Phase 2 Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer May 2009 December 2011
NCT00853931 Completed N/A Biomarker - Panitumumab Response With KRAS Wild Type MCC October 2009 September 2015
NCT00861120 Completed Phase 2 Panitumumab and Pegylated Liposomal Doxorubicin for Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-type April 2009 August 2012
NCT00891930 Completed Phase 2 Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab May 2009 July 2013
NCT00894504 Completed Phase 2 Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer February 2010 September 2014
NCT00940316 Completed Phase 2 Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer January 18, 2010 January 2015
NCT00979212 Completed Phase 2 Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer February 2011 May 20, 2022
NCT01001377 Completed Phase 3 ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer February 2, 2010 March 7, 2017
NCT01036087 Completed Phase 2 Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer November 2010 August 9, 2022
NCT01042288 Completed Phase 2 Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLC June 2010 July 2015
NCT01077999 Completed Phase 2 Chemoradiation and Panitumumab for Esophageal Cancer January 2010 April 2012
NCT01108107 Completed Phase 2 Neoadjuvant Treatment of Colon Cancer April 2010 March 2015
NCT01126112 Completed Phase 2 Study of First-line Single-agent Panitumumab in Frail Elderly Patients With Advanced Wild Type K-RAS Colorectal Cancer May 2010 July 2014
NCT01139138 Completed Phase 1/Phase 2 Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer June 2010 June 2017
NCT01175733 Completed Phase 1/Phase 2 Chemoradiation With Gemcitabine in Combination With Panitumumab for Patients With Locally Advanced Pancreatic Cancer July 8, 2010 May 2016
NCT00814619 Completed Phase 2 Capecitabine and Radiation Therapy With or Without Panitumumab in Treating Patients With Advanced Rectal Cancer November 2008 January 2014
NCT00039273 Completed Phase 2 Monoclonal Antibody Therapy in Treating Patients With Metastatic Colorectal Cancer July 2002
NCT00054574 Completed Phase 2 Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer November 2002 February 2004
NCT00083616 Completed Phase 2 Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy March 2004 December 2008
NCT00089635 Completed Phase 2 Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer August 1, 2004 August 1, 2008
NCT00091806 Completed Phase 1 Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors August 2004 October 2006
NCT00094835 Completed Phase 1/Phase 2 Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) January 2005 March 2007
NCT00111761 Completed Phase 2 Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal Cancer July 2002 October 2008
NCT00113763 Completed Phase 3 Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer January 1, 2004 June 1, 2009
NCT00115765 Completed Phase 3 PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study June 1, 2005 May 1, 2009
NCT00332163 Completed Phase 2 Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy April 2006 September 2008
NCT00339183 Completed Phase 3 Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone June 30, 2006 November 1, 2010
NCT00364013 Completed Phase 3 PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy August 1, 2006 March 22, 2013
NCT00389870 Completed Phase 3 Irinotecan With or Without Panitumumab or Cyclosporine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Fluorouracil December 2006
NCT00411450 Completed Phase 2 Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to Treatment November 2006 October 2010
NCT01202409 Completed Phase 2 CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater November 2, 2010 July 3, 2018
NCT01206049 Completed Phase 2 Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations September 2010 March 2016
NCT01215539 Completed Phase 2 Study of Panitumumab-Capecitabine-Oxaliplatin In Wild-Type K-Ras Metastatic Colorectal Cancer Patients September 2010 December 2014
NCT01226719 Completed Phase 2 FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only December 2010 March 2014
NCT01308840 Completed Phase 2 Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer December 2010 January 2013
NCT01412957 Completed Phase 3 Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer November 2011 November 2016
NCT01443065 Completed Phase 2 MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma January 2011 September 2018
NCT01443377 Completed Phase 2 Neoadjuvant Radiochemotherapy Combined With Panitumumab in Locally Advanced KRAS Wild-type Rectal Cancer July 2011 September 2013
NCT01581840 Completed Phase 1/Phase 2 Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus June 2012 February 2021
NCT01591421 Completed Phase 1/Phase 2 P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer. September 6, 2012 November 12, 2019
NCT01704703 Completed Phase 2 Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques October 2012 July 2016
NCT01750918 Completed Phase 1/Phase 2 BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC) December 19, 2012 June 18, 2020
NCT01776307 Completed Phase 2 A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer March 2012 April 2020
NCT01927341 Completed Phase 1/Phase 2 Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors November 19, 2013 January 25, 2016
NCT02008383 Completed Phase 1 Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer January 2014 August 29, 2018
NCT02089737 Completed Panitumumab for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveillance "Survey on Unresectable, Advanced or Recurrent Colorectal Cancer With Wild-type KRAS Gene" (All-patient Surveillance) June 2010 July 2012
NCT02399943 Completed Phase 2 A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer June 2015 March 31, 2022
NCT02643056 Completed Phase 2 Study to Investigate the Efficacy of Panitumumab in Platinum-resistant Advanced Head and Neck Squamous Cancer January 2011 December 2015
NCT02818725 Completed Phase 3 I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations June 2010 September 2017
NCT03000374 Completed Phase 2 Induction Therapy With Panitumumab + mFOLFOX-6 in Rectal Cancer and Quadruple Wild-type Mutation Before Surgery May 30, 2017 December 15, 2021
NCT03043950 Completed Validation of a New Prognostic Score for Adult Patients With RAS Wild-type mCRC Treated With Vectibix® and FOLFIRI or FOLFOX in First Line (VALIDATE) January 25, 2017 January 17, 2024
NCT03142516 Completed Phase 2 FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status October 31, 2017 January 21, 2021
NCT03231722 Completed Phase 3 First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS September 13, 2017 June 24, 2022
NCT04342676 Completed Phase 3 Lymph Node Ratio and Kras Mutation in R Colon Cancer March 10, 2017 August 26, 2019
NCT04425239 Completed Phase 2 Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer May 21, 2018 April 3, 2022
NCT06268015 Not yet recruiting Phase 2 Botensilimab and Balstilimab Optimization in Colorectal Cancer July 2024 July 2028
NCT04034173 Not yet recruiting Phase 2 Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation August 1, 2019 August 1, 2026
NCT06252649 Not yet recruiting Phase 3 Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation July 1, 2024 December 30, 2030
NCT05423197 Not yet recruiting Phase 2 Study Evaluating Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in Head and Neck Squamous Cell Carcinoma June 2024 December 2024
NCT06245356 Not yet recruiting Phase 2 Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer June 20, 2024 June 21, 2028
NCT04787341 Recruiting Phase 2 PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence December 15, 2020 June 15, 2025
NCT05564377 Recruiting Phase 2 Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial April 7, 2023 July 1, 2030
NCT05638295 Recruiting Phase 2 Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial) October 14, 2024 December 31, 2025
NCT05694936 Recruiting Phase 2 Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer January 23, 2023 September 2024
NCT05747625 Recruiting Phase 1 (89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma May 9, 2023 March 1, 2030
NCT05845450 Recruiting Phase 2 Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) May 11, 2023 May 2028
NCT05863195 Recruiting Phase 3 Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial October 19, 2023 June 30, 2034
NCT02885753 Recruiting Phase 3 Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver December 2016 September 2027
NCT02925234 Recruiting Phase 2 The Drug Rediscovery Protocol (DRUP Trial) August 2016 December 2027
NCT05901545 Recruiting Phase 1 Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer August 22, 2023 November 30, 2029
NCT06194877 Recruiting Phase 1 A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers April 18, 2024 May 24, 2027
NCT03366155 Recruiting Phase 2 Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver June 24, 2019 December 30, 2030
NCT03384238 Recruiting Phase 1/Phase 2 Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery February 7, 2018 September 2027
NCT03510208 Recruiting Phase 1/Phase 2 Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery May 16, 2018 December 31, 2024
NCT04185883 Recruiting Phase 1 Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) December 17, 2019 December 31, 2027
NCT06332079 Recruiting Phase 2 Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients March 13, 2024 February 2027
NCT04587128 Recruiting Phase 2 Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC October 19, 2020 October 2025
NCT05121038 Recruiting Phase 1/Phase 2 CEND-1 in Combination With Neoadjuvant FOLFIRINOX With or Without Panitumumab October 20, 2021 September 2025
NCT01088620 Suspended Phase 2 Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Non-small Cell Lung Cancer April 2010 January 2014
NCT01305772 Terminated Phase 2 Identification of Gene Expression Signature for Panitumumab Sensitivity in Untreated Locally Advanced SCCHN January 2011 May 2012
NCT01307956 Terminated Phase 2 Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer February 28, 2011 December 23, 2015
NCT01843452 Terminated Phase 2 Phase II Study of Concomitant Intensity-modulated Radiotherapy Combined to Capecitabine, Mitomycin and Panitumumab in Patients With Stage II-IIIB Squamous-cell Carcinoma of the Anal Canal December 2012 May 2016
NCT00101907 Terminated Phase 1 Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer December 2004 April 2008
NCT01418742 Terminated Phase 2 SKIP - A Double-blind Placebo-controlled Randomized Multicenter Trial of Skin Toxicity Treatment August 2011 May 2013
NCT02508077 Terminated Phase 2 FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer February 16, 2016 September 13, 2017
NCT01128387 Terminated Phase 1/Phase 2 Trial of Panitumumab/Cisplatin/Fluorouracil Combined With Radiation in Esophageal Cancer May 2010 October 2016
NCT01038037 Terminated Phase 2 First-Line Chemotherapy and Panitumumab in Advanced Non-Small Cell Lung Cancer January 2010 December 2013
NCT01009983 Terminated Phase 2 Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer March 2010 December 2013
NCT03300609 Terminated Phase 3 5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab February 27, 2018 October 3, 2019
NCT03311750 Terminated Phase 2 Anti-EGFR Therapy Rechallenge in Combination With Chemotherapy in Patients With Advanced Colorectal Cancer March 26, 2018 May 20, 2021
NCT00973193 Terminated Phase 2 Preoperative Panitumumab and Radiotherapy in Rectal Cancer September 2009 December 2012
NCT01182610 Terminated Phase 2 Panitumumab, Paclitaxel, Carboplatin and 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma April 2011 March 2012
NCT01916109 Terminated Phase 2 Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer August 2013
NCT01508000 Terminated Phase 2 Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases June 2013 September 2016
NCT00613730 Terminated Phase 2 Adenocarcinoma of the Pancreas Treated With Panitumumab and Gemcitabine Regimen to Investigate Overall Survival as Primary Endpoint January 2007 April 2009
NCT01627379 Terminated Phase 3 Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or Metastatic Esophageal Squamous Cell Cancer May 2012 May 2017
NCT01296035 Terminated Phase 2 Panitumumab and Gemcitabine in Relapsed Ovarian Cancer February 2011 November 2013
NCT01017653 Terminated Phase 2 Panitumumab and Irinotecan for Malignant Gliomas February 2010 October 2011
NCT02476045 Unknown status Phase 2 Panitumumab-based Maintenance in Patients With RAS Wild-type, Metastatic Colorectal Cancer (Valentino) June 2015 July 2018
NCT02301962 Unknown status Phase 4 Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer July 28, 2015 January 31, 2022
NCT01814501 Unknown status Phase 2 Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab February 1, 2013 December 31, 2019
NCT03751176 Unknown status Phase 2 Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal November 8, 2018 November 30, 2022
NCT03940131 Unknown status Phase 2 Re-challenge Therapy With Chemotherapy & Panitumumab in Metastatic Colorectal Cancer Patients Treated With an Anti-EGFR June 10, 2020 July 2022
NCT00967655 Unknown status Phase 2 Capecitabine, Panitumumab, and Radiation Therapy With or Without Irinotecan Hydrochloride in Treating Patients Undergoing Surgery for Localized Rectal Cancer July 2009
NCT00647530 Unknown status Phase 2/Phase 3 Fluorouracil and Oxaliplatin With or Without Panitumumab In Treating Patients With High-Risk Colon Cancer That Can Be Removed by Surgery May 15, 2008 December 31, 2019
NCT01257360 Unknown status Phase 2 Panitumumab in Combination With Radiotherapy in Patients With Locally Advanced RAS Wildtype Rectal Cancer (Clinical Stages II and III) December 2010 July 2016
NCT01384994 Unknown status Phase 2 Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type Patients August 2011 August 2014
NCT01388621 Unknown status Phase 2 Carboplatin-based Chemotherapy With or Without Panitumumab in Platinum-sensitive Recurrent Ovarian Cancer October 2011 July 2015
NCT02904031 Unknown status Phase 2 Study of I Line FOLFOX + Panitumumab vs 5FU + Panitumumab in RAS and BRAF WT Metastatic Colorectal Cancer Elderly Patients July 2016 October 2020
NCT01158248 Unknown status Phase 2 Panitumumab, Cisplatin, and Pelvic Radiation Therapy in Treating Patients With Stage IB, Stage II, or Stage III Cervical Cancer February 2010
NCT01110785 Unknown status Phase 2 Simvastatin and Panitumumab in Treating Patients With Advanced or Metastatic Colorectal Cancer April 2010
NCT01172717 Withdrawn Phase 2 Study of Panitumumab in the Treatment of Carcinoid Syndrome July 2013 July 2013
NCT01312493 Withdrawn Phase 2 Selective IMRT for Locally Advanced Head and Neck Carcinoma With Concurrent Panitumumab December 2011 December 2018
NCT00984217 Withdrawn Phase 2 Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies August 2011 August 2011
NCT01142414 Withdrawn Phase 3 Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients Who Have Undergone Surgery for Advanced Hypopharyngeal Cancer, Oropharyngeal Cancer, Laryngeal Cancer, or Oral Cavity Cancer at High Risk of Recurrence
NCT05177796 Withdrawn Phase 2 Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer March 11, 2022 July 26, 2023
NCT03069950 Withdrawn Phase 2 Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver February 28, 2017 May 16, 2019